Paper Details

  1. Home
  2. Paper Details

The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis.

Author: DavisMat D, DwyerMichael G, KhanOmar, RamasamyDeepa P, SteinermanJoshua R, ZivadinovRobert

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the effect of glatiramer acetate on the evolution of T1 hypointense (T1H) lesions in patients with relapsing-remitting multiple sclerosis (RRMS). The study found that GA40 reduced the number of new or enlarging T1H lesions, but the effect was not significantly different between T1H total and T1H non-enhancing lesions.
Paper Details　
Original Abstract of the Article :
Two definitions of T1 hypointense (T1H) lesions can be derived from pre-contrast images: those that may or may not have a corresponding gadolinium-enhancing correlate on post-contrast images (T1H total), and those that are simultaneously non-gadolinium-enhancing on post-contrast scans (T1H non-enhan...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5054834/

データ提供：米国国立医学図書館（NLM）

Glatiramer Acetate and Cerebral T1 Hypointense Lesions: Navigating the Shifting Sands of MS

Multiple sclerosis (MS) is a complex and unpredictable disease, characterized by the formation of lesions in the brain. This study delves into the effects of glatiramer acetate on the evolution of T1 hypointense (T1H) lesions in patients with relapsing-remitting MS (RRMS). Using a well-defined methodology, the study aims to understand the impact of this medication on the progression of brain lesions, offering valuable insights into the intricate nature of this disease.

The study reveals that glatiramer acetate, administered three times weekly, demonstrated a potential effect on the number of new or enlarging T1H total and T1H non-enhancing lesions in patients with RRMS, suggesting its effectiveness in managing the progression of MS. This is like a skilled camel guide navigating a shifting desert landscape, helping to minimize the impact of shifting sands and protect the traveler from potential hazards.

A Potential Tool for Managing MS Progression

The study underscores the potential of glatiramer acetate as a treatment option for managing MS progression, highlighting its impact on reducing the formation of new or enlarging lesions.

Living with MS: A Journey of Resilience and Hope

The research provides valuable insights into the ongoing efforts to manage MS, offering hope for those living with this challenging condition. It underscores the importance of continued research and development to explore new therapeutic strategies and improve the quality of life for those affected by MS. It’s like a caravan traveling through the desert, each member supporting and encouraging the others to reach their destination.

Dr. Camel's Conclusion

This study, like a compass guiding us through the complexities of MS, offers hope for those navigating this challenging condition. It underscores the potential of glatiramer acetate in managing the progression of the disease, providing a ray of optimism for those seeking to minimize its impact.

Date :
  1. Date Completed 2016-12-13
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

26394270

DOI: Digital Object Identifier

PMC5054834

Related Literature

Article Analysis
・Effects of glatiramer injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.